Extract
We thank S. Couillard for his interesting comments related to our publication on the effects of interleukin (IL)-5 deficiency on the transcriptome of residual eosinophils of Il5-deficient mice and mepolizumab-treated patients [1]. We indeed document stronger upregulation of the expression of the SOCS3 gene following stimulation with IL-33 ex vivo that is conserved between eosinophils from mepolizumab-treated patients and from Il5-deficient mice.
Abstract
It is too early to conclude on a potential biological significance of increased SOCS3 gene expression in blood eosinophils of mepolizumab-treated patients stimulated with interleukin-33 ex vivo https://bit.ly/3wuXMit
Footnotes
Conflict of interest: G. Van Hulst, M. Henket and F. Bureau have nothing to disclose. J. Jorssen reports PhD student scholarship from Fonds de la Recherche scientifique (FRS)-FNRS (Belgium). N. Jacobs reports consultancy and lecture fees from GSK, outside the submitted work. R. Louis reports grants from GSK, AZ, Novartis, Chiesi and Teva; royalties from patents AU2016328384, CA2997506, EP 3337393 and US2020345266; consulting fees and lecture payments from GSK, AZ, Novartis, Sanofi and Chiesi, outside the submitted work. F. Schleich reports grants from GSK, AstraZeneca, Teva, Chiesi and Novartis; consulting fees from GSK, AstraZeneca, Amgen, Chiesi and Novartis; lecture payments from GSK, AstraZeneca, Teva, Chiesi and Novartis, outside the submitted work. C.J. Desmet reports salary from Fonds de la Recherche Scientifique – FNRS (Belgium), during the submitted work; consulting fees from AstraZeneca; lecture fees for presentations at several scientific symposia from GSK, outside the submitted work.
- Received May 12, 2022.
- Accepted May 16, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org